[{"id":"ac98ef23-c100-4250-a77b-e2d769f12f8d","acronym":"NCI-2020-02940","url":"https://clinicaltrials.gov/study/NCT04445844","created_at":"2021-01-18T21:23:42.652Z","updated_at":"2024-07-02T16:35:11.834Z","phase":"Phase 2","brief_title":"INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study","source_id_and_acronym":"NCT04445844 - NCI-2020-02940","lead_sponsor":"Mridula George, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • Zynyz (retifanlimab-dlwr) • Reolysin (pelareorep)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-04-02"},{"id":"dc767eda-b996-43e4-bac4-42c5a7f4d226","acronym":"BRACELET-1","url":"https://clinicaltrials.gov/study/NCT04215146","created_at":"2021-01-18T20:31:29.086Z","updated_at":"2024-07-02T16:35:27.596Z","phase":"Phase 2","brief_title":"A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study","source_id_and_acronym":"NCT04215146 - BRACELET-1","lead_sponsor":"Oncolytics Biotech","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 overexpression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Bavencio (avelumab) • Reolysin (pelareorep)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 06/10/2020","start_date":" 06/10/2020","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-11-30"},{"id":"b3af7af9-f90a-43d8-a825-1d8fe6b331f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05519059","created_at":"2022-08-29T13:03:02.753Z","updated_at":"2024-07-02T16:35:28.248Z","phase":"Phase 1","brief_title":"Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05519059","lead_sponsor":"Adlai Nortye Biopharma Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Reolysin (pelareorep)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 10/11/2021","start_date":" 10/11/2021","primary_txt":" Primary completion: 09/29/2022","primary_completion_date":" 09/29/2022","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2023-11-22"},{"id":"4c303da3-0333-482c-a447-3a810066c7aa","acronym":"AMBUSH","url":"https://clinicaltrials.gov/study/NCT05514990","created_at":"2023-11-18T23:15:37.982Z","updated_at":"2024-07-02T16:35:28.859Z","phase":"Phase 1/2","brief_title":"Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial","source_id_and_acronym":"NCT05514990 - AMBUSH","lead_sponsor":"University of Southern California","biomarkers":" CD8 • PD-1 • IFNG • CD4 • GZMB","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • IFNG • CD4 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bortezomib • Reolysin (pelareorep) • Hemady (dexamethasone tablets) • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 10/07/2025","primary_completion_date":" 10/07/2025","study_txt":" Completion: 10/07/2026","study_completion_date":" 10/07/2026","last_update_posted":"2023-11-17"},{"id":"c927ffd4-5216-4a18-a436-db4d0c37cf50","acronym":"","url":"https://clinicaltrials.gov/study/NCT01199263","created_at":"2021-01-18T04:48:14.391Z","updated_at":"2024-07-02T16:36:40.957Z","phase":"Phase 2","brief_title":"Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT01199263","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Reolysin (pelareorep)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 12/06/2010","start_date":" 12/06/2010","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 07/17/2020","study_completion_date":" 07/17/2020","last_update_posted":"2020-09-16"},{"id":"74abfb55-613a-4e31-a6b8-f6f55f7a5d6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01274624","created_at":"2021-01-18T05:10:06.565Z","updated_at":"2024-07-02T16:37:04.536Z","phase":"Phase 1","brief_title":"Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01274624","lead_sponsor":"Oncolytics Biotech","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Reolysin (pelareorep)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2018-12-19"},{"id":"7bc82656-0e7b-40da-a3a1-4012ebf9a278","acronym":"","url":"https://clinicaltrials.gov/study/NCT02723838","created_at":"2021-01-18T13:19:39.026Z","updated_at":"2024-07-02T16:37:24.687Z","phase":"Phase 1b","brief_title":"Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder","source_id_and_acronym":"NCT02723838","lead_sponsor":"Oncolytics Biotech","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Reolysin (pelareorep)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/28/2017","start_date":" 02/28/2017","primary_txt":" Primary completion: 09/30/2017","primary_completion_date":" 09/30/2017","study_txt":" Completion: 02/28/2018","study_completion_date":" 02/28/2018","last_update_posted":"2017-03-07"}]